N-(1-benzylpiperidin-4-yl)-N-phenylacrylamide | 1956368-29-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(1-benzylpiperidin-4-yl)-N-phenylacrylamide
• 英文别名: Benzyl acrylfentanyl；N-(1-benzylpiperidin-4-yl)-N-phenylprop-2-enamide
• CAS: 1956368-29-8
• 化学式: C₂₁H₂₄N₂O
• 分子量: 320.434
• InChiKey: BANFGBDVLADRGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-苯胺-1-苯甲基哌啶 、 丙烯酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 7.0h， 以64%的产率得到N-(1-benzylpiperidin-4-yl)-N-phenylacrylamide
  参考文献：
  名称：

  [EN] AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS
  [FR] CARTE DE GUIDE D'ACTIVITÉ D'INTERACTIONS ÉLECTROPHILE-CYSTÉINE DANS DES CELLULES IMMUNITAIRES HUMAINES PRIMAIRES

  摘要：

  公开号：

  WO2021076755A8

文献信息

• Cysteine reactive probes and uses thereof
  申请人：The Scripps Research Institute

  公开号：US10670605B2

  公开（公告）日：2020-06-02

  Disclosed herein are methods, compositions, probes, polypeptides, assays, and kits for identifying a cysteine containing protein as a binding target for a small molecule fragment. Also disclosed herein are methods, compositions, and probes for mapping a biologically active cysteine site on a protein and screening a small molecule fragment for interaction with a cysteine containing protein.

  本文公开了用于鉴定含半胱氨酸蛋白质作为小分子片段结合靶点的方法、组合物、探针、多肽、检测方法和试剂盒。本文还公开了用于绘制蛋白质上的生物活性半胱氨酸位点以及筛选与含半胱氨酸蛋白质相互作用的小分子片段的方法、组合物和探针。
• In vivo engineered cereblon protein
  申请人：Vividion Therapeutics, Inc.

  公开号：US10781239B2

  公开（公告）日：2020-09-22

  Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3.

  本文公开了体内工程化脑龙蛋白及其制造方法。体内工程化脑龙蛋白可包括 SEQ ID NO:1 所列半胱氨酸 287 或 SEQ ID NO:2 或 3 所列半胱氨酸 286 的位点特异性非天然发生修饰，该修饰包括外源迈克尔受体与 SEQ ID NO:1 所列半胱氨酸 287 或 SEQ ID NO:2 或 3 所列半胱氨酸 286 之间的体内迈克尔加成反应产生的分子。
• CYSTEINE REACTIVE PROBES AND USES THEREOF
  申请人：The Scripps Research Institute

  公开号：EP3365686A1

  公开（公告）日：2018-08-29
• COMPOSITIONS AND METHODS OF MODULATING IMMUNE RESPONSE
  申请人：The Scripps Research Institute

  公开号：US20190216893A1

  公开（公告）日：2019-07-18

  Disclosed herein are methods, pharmaceutical compositions, and vaccines for modulating an immune response. Also disclosed, herein are methods, pharmaceutical compositions, and vaccines for inducing an immune response.
• IN VIVO ENGINEERED CEREBLON PROTEIN
  申请人：Vividion Therapeutics, Inc.

  公开号：US20200216507A1

  公开（公告）日：2020-07-09

  Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO: 2 or 3.